The antitumor activity of osimertinib plus palbociclib in non-small cell lung cancer patient-derived xenograft (PDX)/2D/3D culture models harboring EGFR amplification and CDKN2A/2B homozygous deletions

被引:1
作者
Fu, Jen-Fen [1 ]
Hsu, Cheng-Lung [2 ]
Hsu, Ping-Chih [3 ]
机构
[1] Chang Gung Mem Hosp, Dept Med Res, 5 Fu Hsin St, Taoyuan 333, Taiwan
[2] Chang Gung Univ, Chang Gung Mem Hosp, Dept Internal Med, Div Hematol Oncol, 5 Fu Hsin St, Taoyuan 333, Taiwan
[3] Chang Gung Univ, Chang Gung Mem Hosp, Dept Thorac Med, Taoyuan, Taiwan
来源
NEOPLASIA | 2024年 / 57卷
关键词
Non-small cell lung cancer; Wildtype EGFR; amplification; CDKN2A/2B homozygous; deletions; PDX/2D/3D cell model; Osimertinib; Palbociclib; CLINICAL SPECIMENS; TUMOR ENGRAFTMENT; GROWTH; GENE; ERLOTINIB; LINES;
D O I
10.1016/j.neo.2024.101039
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Non-small cell lung cancer (NSCLC) patients without targetable driver mutation have limited treatment options. In this study, we aimed to explore a new therapeutic strategy by using established nine patient-derived xenograft (PDX) and two-dimensional (2D) /3D culture models with specific genetic alternations. The gene mutations and copy number aberrations were detected by next-generation sequencing and confirmed using polymerase chain reaction (PCR) followed by DNA sequencing, and genomic DNA quantitative PCR. Protein expression was evaluated by immunohistochemistry. Drug sensitivities of PDX/2D/3D models were evaluated by in vivo and in vitro antitumor assays. RNA interference was performed to silence gene expression. Our study found that 44.4 % (4/9) of cases had CDKN2A homozygous deletion (homdel), while 33.3 % (3/9) had CDKN2B homdel. Additionally, 22.2 % (2/9) had amplification (amp) in wildtype CDK4, 44.4 % (4/9) in CDK6, and 44.4 % (4/9) in EGFR. Among the cases, 77.8 % (7/9) lacked CDKN2A, and 33.3 % (3/9) had high CDK4, CDK6, and EGFR had high protein expression. Moreover, 33.3 % (3/9) had KRAS mutations, and 66.7 % (6/9) had TP53 mutations. Antitumor activity of osimertinib plus palbociclib was assessed in four PDX/2D/3D models, two of which had simultaneous EGFR amp and CDKN2A/2B homdel. The data showed that NSCLC with EGFR amp and CDKN2A/ 2B homdel were sensitive to combined drugs. Additional oncogenic KRAS mutation reduced the drug's antitumor effect. EGFR amp is responsible for osimertinib sensitivity. Osimertinib plus palbociclib effectively treat NSCLC with wildtype EGFR and CDK6 amp and CDKN2A/2B homdel in the absence of oncogenic KRAS mutation.
引用
收藏
页数:10
相关论文
共 22 条
  • [1] Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227
    Brahmer, Julie R.
    Lee, Jong-Seok
    Ciuleanu, Tudor-Eliade
    Bernabe Caro, Reyes
    Nishio, Makoto
    Urban, Laszlo
    Audigier-Valette, Clarisse
    Lupinacci, Lorena
    Sangha, Randeep
    Pluzanski, Adam
    Burgers, Jacobus
    Mahave, Mauricio
    Ahmed, Samreen
    Schoenfeld, Adam J.
    Paz-Ares, Luis G.
    Reck, Martin
    Borghaei, Hossein
    O'Byrne, Kenneth J.
    Gupta, Ravi G.
    Bushong, Judith
    Li, Li
    Blum, Steven I.
    Eccles, Laura J.
    Ramalingam, Suresh S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (06) : 1200 - +
  • [2] Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
    Bray, Freddie
    Laversanne, Mathieu
    Sung, Hyuna
    Ferlay, Jacques
    Siegel, Rebecca L.
    Soerjomataram, Isabelle
    Jemal, Ahmedin
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2024, 74 (03) : 229 - 263
  • [3] BROWER M, 1986, CANCER RES, V46, P798
  • [4] Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
    Cappuzzo, F
    Hirsch, FR
    Rossi, E
    Bartolini, S
    Ceresoli, GL
    Bemis, L
    Haney, J
    Witta, S
    Danenberg, K
    Domenichini, I
    Ludovini, V
    Magrini, E
    Gregorc, V
    Doglioni, C
    Sidoni, A
    Tonato, M
    Franklin, WA
    Crino, L
    Bunn, PA
    Varella-Garcia, M
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (09): : 643 - 655
  • [5] Increase in the Life Expectancy of Patients with Cancer in the United States
    Devasia, Theresa P.
    Howlader, Nadia
    Dewar, Ron A.
    Stevens, Jennifer L.
    Mittu, Karen
    Mariotto, Angela B.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (02) : 196 - 205
  • [6] TUMOR MEASUREMENT IN THE NUDE-MOUSE
    EUHUS, DM
    HUDD, C
    LAREGINA, M
    JOHNSON, FE
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 1986, 31 (04) : 229 - 234
  • [7] Tumor Engraftment in Nude Mice and Enrichment in Stroma-Related Gene Pathways Predict Poor Survival and Resistance to Gemcitabine in Patients with Pancreatic Cancer
    Garrido-Laguna, Ignacio
    Uson, Maria
    Rajeshkumar, N. V.
    Tan, Aik Choon
    de Oliveira, Elizabeth
    Karikari, Collins
    Villaroel, Maria C.
    Salomon, Ana
    Taylor, Gretchen
    Sharma, Rajni
    Hruban, Ralph H.
    Maitra, Anirban
    Laheru, Daniel
    Rubio-Viqueira, Belen
    Jimeno, Antonio
    Hidalgo, Manuel
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (17) : 5793 - 5800
  • [8] GAZDAR AF, 1986, CANCER RES, V46, P6011
  • [9] Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial
    Gregorc, Vanesa
    Novello, Silvia
    Lazzari, Chiara
    Barni, Sandro
    Aieta, Michele
    Mencoboni, Manlio
    Grossi, Francesco
    De Pas, Tommaso
    de Marinis, Filippo
    Bearz, Alessandra
    Floriani, Irene
    Torri, Valter
    Bulotta, Alessandra
    Cattaneo, Angela
    Grigorieva, Julia
    Tsypin, Maxim
    Roder, Joanna
    Doglioni, Claudio
    Levra, Matteo Giaj
    Petrelli, Fausto
    Foti, Silvia
    Vigano, Mariagrazia
    Bachi, Angela
    Roder, Heinrich
    [J]. LANCET ONCOLOGY, 2014, 15 (07) : 713 - 721
  • [10] Anticancer drug development: the grand challenges
    Hait, William N.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (04) : 253 - 254